Autoantibodies to extracellular matrix protein 1 in lichen sclerosus

Lancet

Volumn 362, Issue 9378, 2003, Pages 118-123

  Oyama, Noritaka ^a   Chan, Ien ^a   Neill, Sallie M ^a   Hamada, Takahiro ^a   South, Andrew P ^a   Wessagowit, Vesarat ^a   Wojnarowska, Fenella ^b   D'Cruz, David ^c   Hughes, Graham J ^c   Black, Martin M ^a   McGrath, John A ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; EXTRACELLULAR MATRIX PROTEIN 1; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; RECOMBINANT PROTEIN; SCLEROPROTEIN; UNCLASSIFIED DRUG;

ABSORPTION; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOREACTIVITY; LICHEN SCLEROSUS ET ATROPHICUS; LIPOID PROTEINOSIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SAMPLING; SKIN; STAINING; TITRIMETRY;

EID: 0037629268     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13863-9     Document Type: Article

References (30)

1. Meffert J.J., Davis B.M., Grimwood R.E. Lichen sclerosus. J Am Acad Dermatol. 32:1995;393-416.
2. Tasker G.L., Wojnarowska F. Lichen sclerosus. Clin Exp Dermatol. 28:2003;128-133.
3. Powell J.J., Wojnarowska F. Lichen sclerosus. Lancet. 353:1999;1777-1783.
4. Wallace H.J. Lichen sclerosus et atrophicus, Trans St John. s Hosp Dermatol Soc. 57:1971;9-30.
5. Meyrick Thomas R.H., Ridley C.M., McGibbon D.H., Black M.M. Lichen sclerosus et atrophicus and autoimmunity: a study of 350 women. Br J Dermatol. 118:1998;41-46.
6. Meyrick Thomas R.H., Kennedy C.T. The development of lichen sclerosus et atrophicus in monozygotic twin girls. Br J Dermatol. 114:1986;377-379.
7. Sahn E.E., Bluestein E.L., Oliva S. Familial lichen sclerosus et atrophicus in childhood. Pediatr Dermatol. 11:1994;160-163.
8. Azurdia R.M., Luzzi G.A., Byren I., et al. Lichen sclerosus in adult men: a study of HLA associations and susceptibility to autoimmune disease. Br J Dermatol. 140:1999;79-83.
9. Powell J.J., Wojnarowska F., Winsey S., et al. Lichen sclerosus premenarche: autoimmunity and immunogenetics. Br J Dermatol. 142:2000;481-484.
10. Chan L.S., Ahmed A.R., Anhalt G.J., et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 138:2002;370-379.
11. Harrington C.I., Dunsmore I.R. An investigation into the incidence of auto-immune disorders in patients with lichen sclerosus and atrophicus. Br J Dermatol. 104:1981;563-566.
12. Bernard P., Prost C., Durepaire N., et al. The major cicatricial pemphigoid antigen is a 180-kD protein that shows immunologic cross-reactivities with the bullous pemphigoid antigen. J Invest Dermatol. 99:1992;174-179.
13. Domloge-Hultsch N., Anhalt G.J., Gammon W.R., et al. Antiepiligrin cicatricial pemphigoid: a subepithelial bullous disorder. Arch Dermatol. 130:1994;1521-1529.
14. McGrath J.A., Pulkkinen L., Christiano A.M., et al. Altered laminin 5 expression due to mutations in the gene encoding the beta 3 chain (LAMB3) in generalized atrophic benign epidermolysis bullosa. J Invest Dermatol. 104:1995;467-474.
15. McGrath J.A., Gatalica B., Christiano A.M., et al. Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nat Genet. 11:1995;83-86.
16. Hamada T., McLean W.H., Ramsay M., et al. Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene (ECM1). Hum Mol Genet. 11:2002;833-840.
17. Hamada T., Wessagowit V., South A.P., et al. Extracellular matrix protein 1 gene (ECM1) mutations in lipoid proteinosis and genotype-phenotype correlation. J Invest Dermatol. 120:2003;345-350.
18. Smits P., Poumay Y., Karperien M., et al. Differentiation-dependent alternative splicing and expression of the extracellular matrix protein 1 gene in human keratinocytes. J Invest Dermatol. 114:2000;718-724.
19. Han Z., Ni J., Smits P., et al. Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. FASEB J. 15:2001;988-994.
20. Mongiat M., Fu J., Oldershaw R., et al. Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis. J Biol Chem. 278:2003;17491-17499.
21. Ohata Y., Hashimoto T., Nishikawa T. Comparative study of autoantigens for various bullous skin diseases by immunoblotting using different dermo-epidermal separation techniques. Clin Exp Dermatol. 20:1995;454-458.
22. Oyama N., Iwatsuki K., Homma Y., et al. Induction of transcription factor AP-2 by inflammatory cytokines in human keratinocytes. J Invest Dermatol. 113:1999;600-606.
23. Black M.M., Bhogal B.S. Diagnosis, diagnostic and research techniques. Briggaman R.A., Wojnarowska F. Management of blistering diseases. 1990;15-34 Raven Press, New York.
24. Smits P., Ni J., Feng P., et al. The human extracellular matrix gene 1 (ECM1): genomic structure, cDNA cloning, expression pattern, and chromosomal localization. Genomics. 45:1997;487-495.
25. Bushkell L.L., Friedrich E.G. Jr, Jordon R.E. An appraisal of routine direct immunofluorescence in vulvar disorders. Acta Derm Venereol. 61:1981;157-161.
26. Jonkman M.F. Hereditary skin diseases of hemidesmosomes. J Dermatol Sci. 20:1999;103-121.
27. Zillikens D. Acquired skin diseases of hemidesmosomes. J Dermatol Sci. 20:1999;134-154.
28. Macfarlane A.W., Verbov J.L. Trauma-induced bullous pemphigoid. Clin Exp Dermatol. 14:1989;245-249.
29. Yancey K.B., Egan C.A. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA. 284:2000;350-356.
30. Irvine H.G. Idiopathic atrophy of the skin. JAMA. 61:1913;396-400.